

Antonino Musolino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6214027/publications.pdf>

Version: 2024-02-01

128
papers

5,041
citations

279487

23
h-index

95083

68
g-index

136
all docs

136
docs citations

136
times ranked

6834
citing authors

#	ARTICLE	IF	CITATIONS
1	20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. <i>New England Journal of Medicine</i> , 2017, 377, 1836-1846.	13.9	1,052
2	Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/3 Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1789-1796.	0.8	940
3	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. <i>Lancet Oncology</i> , The, 2018, 19, 27-39.	5.1	717
4	Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2 Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 1989-1995.	0.8	330
5	Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 573.	3.4	217
6	Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. <i>Annals of Oncology</i> , 2018, 29, 2328-2333.	0.6	124
7	Multifactorial central nervous system recurrence susceptibility in patients with HER2 positive breast cancer. <i>Cancer</i> , 2011, 117, 1837-1846.	2.0	119
8	BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study. <i>Breast</i> , 2007, 16, 280-292.	0.9	114
9	Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2 breast cancer that had progressed during or after prior endocrine therapy. <i>Breast Cancer Research</i> , 2017, 19, 18.	2.2	87
10	Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. <i>Oncologist</i> , 2015, 20, 1001-1010.	1.9	85
11	SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1000-1000.	0.8	71
12	Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. <i>Annals of Oncology</i> , 2019, 30, 418-423.	0.6	66
13	Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review. <i>Translational Oncology</i> , 2020, 13, 410-422.	1.7	52
14	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology</i> , The, 2020, 21, 1455-1464.	5.1	52
15	Salivary MicroRNA for Diagnosis of Cancer and Systemic Diseases: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 907.	1.8	51
16	Role of Fcγ3 receptors in HER2-targeted breast cancer therapy. , 2022, 10, e003171.		47
17	Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. <i>Cancer</i> , 2011, 117, 964-973.	2.0	41
18	Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. <i>Cancer Research</i> , 2022, 82, 1646-1657.	0.4	40

#	ARTICLE	IF	CITATIONS
19	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. <i>European Journal of Cancer</i> , 2017, 82, 237-246.	1.3	38
20	Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study. <i>Breast</i> , 2019, 48, 7-16.	0.9	37
21	Evaluation of HER-2/Neu Amplification and Other Biological Markers as Predictors of Response to Neoadjuvant Anthracycline-Based Chemotherapy in Primary Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 171-177.	0.6	36
22	Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 308-317.	3.2	36
23	Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 409-424.	1.6	33
24	9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER.. <i>Journal of Clinical Oncology</i> , 2017, 35, 501-501.	0.8	26
25	Human Epidermal Growth Factor Receptor 2 Status and Interval Breast Cancer in a Population-Based Cancer Registry Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2362-2368.	0.8	25
26	A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 601-609.	1.1	25
27	Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study. <i>Clinical Cancer Research</i> , 2021, 27, 5482-5491.	3.2	25
28	A breast cancer patient from Italy with germline mutations in both the <i>BRCA1</i> and <i>BRCA2</i> genes. <i>Breast Cancer Research and Treatment</i> , 2005, 91, 203-205.	1.1	24
29	Abstract GS1-02: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis. <i>Cancer Research</i> , 2020, 80, GS1-02-GS1-02.	0.4	24
30	Prognostic impact of HER2 overexpression/amplification in women with pT1a NO MO breast cancer with known screening status: First results from a multicenter population-based cancer registry study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 594-594.	0.8	23
31	Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer. <i>Pharmacogenomics Journal</i> , 2016, 16, 472-477.	0.9	22
32	Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial).. <i>Journal of Clinical Oncology</i> , 2011, 29, 507-507.	0.8	22
33	Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. <i>Pharmacogenomics Journal</i> , 2014, 14, 14-19.	0.9	21
34	Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2 ⁻) advanced breast cancer patients: New insights beyond clinical trials. The EVA study. <i>Breast</i> , 2017, 35, 115-121.	0.9	21
35	Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. <i>European Journal of Cancer</i> , 2021, 153, 133-141.	1.3	20
36	Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids. <i>British Journal of Haematology</i> , 2009, 145, 84-86.	1.2	19

#	ARTICLE	IF	CITATIONS
37	Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2019, 9, 759.	1.3	18
38	The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1051-1057.	1.1	17
39	<i>PIK3CA</i> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. <i>Clinical Cancer Research</i> , 2020, 26, 5843-5851.	3.2	17
40	p73 and p53 Pathway in Human Breast Cancers. <i>Journal of Clinical Oncology</i> , 2007, 25, 1451-1453.	0.8	16
41	Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 149, 102927.	2.0	15
42	Accuracy and Relative Value of Bone Marrow Aspiration in the Detection of Lymphoid Infiltration in non-Hodgkin Lymphoma. <i>Tumori</i> , 2010, 96, 24-27.	0.6	14
43	Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, e65-e75.	1.1	14
44	Early Detection of Recurrences in the Follow-up of Primary Breast Cancer in an Asymptomatic or Symptomatic Phase. <i>Tumori</i> , 2004, 90, 276-279.	0.6	13
45	Molecular Profile and Clinical Variables in Brca1-Positive Breast Cancers. A Population-Based Study. <i>Tumori</i> , 2005, 91, 505-512.	0.6	13
46	Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient. <i>Annals of Oncology</i> , 2017, 28, 1405-1406.	0.6	13
47	Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review. <i>Acta Biomedica</i> , 2017, 88, 329-333.	0.2	13
48	Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). <i>ESMO Open</i> , 2021, 6, 100019.	2.0	12
49	Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998-2012. <i>Cancer Medicine</i> , 2021, 10, 6855-6867.	1.3	12
50	A review of immune checkpoint blockade in breast cancer. <i>Seminars in Oncology</i> , 2021, 48, 208-225.	0.8	11
51	The relative contribution of the decreasing trend in tumour thickness to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population-based investigation*. <i>British Journal of Dermatology</i> , 2022, 187, 52-63.	1.4	11
52	Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers. <i>Cancer Treatment Reviews</i> , 2016, 43, 1-7.	3.4	10
53	Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma. <i>Cancer</i> , 2005, 103, 2109-2117.	2.0	9
54	Intracranial hematopoiesis in a patient with aids-related central nervous system lymphoma and severe pancytopenia. <i>Haematologica</i> , 2007, 92, e59-e61.	1.7	8

#	ARTICLE	IF	CITATIONS
55	162MO Neoadjuvant chemotherapy and immunotherapy in Luminal B BC: Results of the phase II GIADA trial. <i>Annals of Oncology</i> , 2020, 31, S304-S305.	0.6	7
56	Abstract PD5-1: Results from the phase 2 trial of ridaforolimus, dalotuzumab, and exemestane compared to ridaforolimus and exemestane in advanced breast cancer. <i>Cancer Research</i> , 2015, 75, PD5-1-PD5-1.	0.4	7
57	Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers. <i>Frontiers in Oncology</i> , 2021, 11, 700853.	1.3	6
58	Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 415-424.	1.1	6
59	PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 544-544.	0.8	6
60	Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study. <i>Acta Biomedica</i> , 2016, 87, 54-63.	0.2	6
61	Molecular Subtypes, Metastatic Pattern and Patient Age in Breast Cancer: An Analysis of Italian Network of Cancer Registries (AIRTUM) Data. <i>Journal of Clinical Medicine</i> , 2021, 10, 5873.	1.0	6
62	Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe. <i>Breast</i> , 2021, 59, 232-238.	0.9	5
63	Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/neu-positive metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 13090-13090.	0.8	5
64	Lung cancer in patients with chronic lymphocytic leukemia. <i>Lung Cancer</i> , 2005, 50, 419-420.	0.9	4
65	Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial. <i>BMC Medicine</i> , 2019, 17, 207.	2.3	4
66	410 Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trial. <i>Annals of Oncology</i> , 2021, 32, S37.	0.6	4
67	Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study. <i>Oncotarget</i> , 2018, 9, 31877-31887.	0.8	4
68	Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis. <i>Cancer Research</i> , 2022, 82, PD8-01-PD8-01.	0.4	4
69	9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio. <i>Annals of Oncology</i> , 2018, 29, viii705.	0.6	3
70	Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPiO study. <i>Journal of Geriatric Oncology</i> , 2019, 10, 990-993.	0.5	3
71	Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis. <i>Frontiers in Oncology</i> , 2020, 10, 192.	1.3	3
72	Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force. <i>ESMO Open</i> , 2022, 7, 100483.	2.0	3

#	ARTICLE	IF	CITATIONS
73	Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer. <i>Annals of Oncology</i> , 2017, 28, vi1.	0.6	2
74	Prognostic impact of interval breast cancer detection in women with pT1a NOMO breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study. <i>European Journal of Cancer</i> , 2018, 88, 10-20.	1.3	2
75	PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors. <i>Annals of Oncology</i> , 2019, 30, v760.	0.6	2
76	19P PIK3CA mutations in HER2-positive early breast cancer patients enrolled in the adjuvant randomized short-HER study. <i>Annals of Oncology</i> , 2020, 31, S23.	0.6	2
77	Abstract OT2-6-04: Dovitinib, a receptor tyrosine kinase inhibitor in combination with fulvestrant in postmenopausal endocrine resistant human epidermal growth factor receptor 2 negative (HER2-) / hormone receptor-positive (HR+) breast cancer: A phase II, randomized, double blind, placebo-controlled study. . 2013. . .		2
78	Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 582-582.	0.8	2
79	Abstract P1-14-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). <i>Cancer Research</i> , 2019, 79, P1-14-05-P1-14-05.	0.4	2
80	Breast Cancer in Italy: Stage and Region Distribution. <i>Breast Cancer: Targets and Therapy</i> , 2022, Volume 14, 125-131.	1.0	2
81	Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492110434.	0.6	1
82	Is Anti-Müllerian Hormone a Marker of Ovarian Reserve in Young Breast Cancer Patients Receiving a GnRH Analog during Chemotherapy?. <i>Breast Care</i> , 2022, 17, 10-15.	0.8	1
83	129P Integration of gene expression and tumor-infiltrating lymphocytes (TILs) to predict pCR after neoadjuvant chemotherapy and nivolumab for patients with luminal B-like breast cancer in the phase II GIADA trial. <i>Annals of Oncology</i> , 2021, 32, S414.	0.6	1
84	PD05-01: Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer.. , 2011, , .		1
85	Dovitinib plus fulvestrant in postmenopausal endocrine resistant HER2-/ HR+ breast cancer: A phase II, randomized, placebo-controlled study.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS651-TPS651.	0.8	1
86	Abstract OT1-03-03: Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable or locally advanced/Inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). , 2018, , .		1
87	Integrated MRI-Immune-Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma. <i>Cancers</i> , 2022, 14, 3249.	1.7	1
88	Reply to activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. <i>Cancer</i> , 2011, 117, 3531-3531.	2.0	0
89	BrcA Status, Molecular Profile and Clinical Variables in Primary Bilateral Breast Cancers: A Population-Based Cancer Registry Study. <i>Annals of Oncology</i> , 2012, 23, ix175-ix176.	0.6	0
90	BOLERO-3 results: pharmacological activity or pharmacokinetic effect?. <i>Lancet Oncology</i> , The, 2014, 15, e304.	5.1	0

#	ARTICLE	IF	CITATIONS
91	1849 Italian observational study of Eribulin Mesylate in patients with advanced breast cancer: ESEMPIO study. <i>European Journal of Cancer</i> , 2015, 51, S281-S282.	1.3	0
92	Prognostic Impact of Interval Breast Cancer Detection in Women with pT1aN0M0 Breast Cancer with HER2-positive Status: Results from a Multicenter Population-based Cancer Registry Study. <i>Annals of Oncology</i> , 2016, 27, iv61.	0.6	0
93	FCGR, Cetuximab, and Colorectal Cancer Survival—Letter. <i>Clinical Cancer Research</i> , 2016, 22, 4958-4958.	3.2	0
94	Prognostic Role of Immunoglobulin G Fragment C Receptor Polymorphisms in Solid Tumors. <i>JAMA Oncology</i> , 2018, 4, 132.	3.4	0
95	Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial. <i>Annals of Oncology</i> , 2018, 29, viii58-viii59.	0.6	0
96	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. <i>Breast Care</i> , 2020, 15, 30-37.	0.8	0
97	Abstract PS10-24: Infusion related reactions in the phase 3 SOPHIA trial of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with pretreated HER2+ metastatic breast cancer. , 2021, , .		0
98	Abstract PS4-33: Androgen receptors are highly expressed in HER2-positive breast cancers that achieve pCR to anti-HER2 monoclonal antibodies. , 2021, , .		0
99	Abstract PD10-04: Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens. , 2021, , .		0
100	Abstract OT-31-01: A phase II study to evaluate the efficacy and safety of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer: PEMBRACA trial. , 2021, , .		0
101	1587P SARS-CoV-2 infection risk and COVID-19 prevalence in cancer patients during the first wave of COVID-19 pandemic in a Northern Italy's virus epicenter area. <i>Annals of Oncology</i> , 2021, 32, S1142.	0.6	0
102	145P High-risk breast cancer patients with RAD51-low tumors are characterized by good prognosis. <i>Annals of Oncology</i> , 2021, 32, S423-S424.	0.6	0
103	376—RAD51 RING trial: a European interlaboratory analytical validation to determine the robustness of RAD51 as a biomarker for homologous recombination. , 2021, , .		0
104	Different expression of BRCA1 status and clinical variables in a sample of Italian women with early onset breast cancer (EOBC). <i>Journal of Clinical Oncology</i> , 2004, 22, 9670-9670.	0.8	0
105	Male breast cancer in Parma Province: Descriptive epidemiology, molecular markers and clinical variables. <i>Journal of Clinical Oncology</i> , 2004, 22, 9655-9655.	0.8	0
106	BRCA1 status, molecular markers, clinical variables in breast cancer patients with high probability of having an inherited genetic mutation. <i>Journal of Clinical Oncology</i> , 2004, 22, 9648-9648.	0.8	0
107	The development of a preoperative chemotherapy strategy for patients selected to undergo pulmonary metastasectomy from colorectal cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 3653-3653.	0.8	0
108	Multifactorial CNS relapse susceptibility in HER2-positive breast cancer patients: First results from a population-based registry study. <i>Journal of Clinical Oncology</i> , 2009, 27, 1117-1117.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Abstract P2-04-01: HER2 Status as Predictor of Mammographic Screening Detection: Comparison of Interval-and Screen-Detected Breast Cancers. , 2010, , .		0
110	Abstract P5-12-05:9Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. , 2010, , .		0
111	Abstract P2-17-01: Phase II Study of Bevacizumab in Combination with Docetaxel and Capecitabine for the First-Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer. , 2010, , .		0
112	Abstract 4646: Notch and DLL4 expression in bevacizumab-treated colon cancer patients.. , 2013, , .		0
113	Abstract P3-06-23: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in patients with HER2-positive operable breast cancer. , 2015, , .		0
114	Family history for BRCA1 and BRCA2 mutations in patients with pancreatic cancer: An observational, population-based study.. Journal of Clinical Oncology, 2015, 33, e15236-e15236.	0.8	0
115	Abstract OT3-02-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer. ERIGE Trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). , 2016, , .		0
116	Abstract P1-07-23: Prognostic impact of HER2 overexpression/amplification in women with pT1a NO MO breast cancer with known screening status: Results from a multicenter population-based cancer registry study. , 2016, , .		0
117	Brain metastasis (BM) prediction by transcriptomic profiling in triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2016, 34, 1076-1076.	0.8	0
118	Direct radiolabeling of nivolumab with Ga-68: A novel PET tracer to detect PD-1 expressing tumors. Medical and Clinical Archives, 2017, 1, .	0.0	0
119	Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).. Journal of Clinical Oncology, 2017, 35, 1095-1095.	0.8	0
120	Abstract P1-13-02: Withdrawn. , 2018, , .		0
121	Salivary microRNA for diagnosis of systemic diseases and malignant tumors: a systematic review. Frontiers in Physiology, 0, 10, .	1.3	0
122	Abstract P1-18-04: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: Infusion time substudy results. , 2020, , .		0
123	Abstract P1-18-19: Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable, locally advanced, or inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).. 2020, , .		0
124	The future potential of genome-wide mutational profiles in HRD detection in breast cancer. Expert Review of Molecular Diagnostics, 2022, 22, 1-3.	1.5	0
125	The development of a preoperative chemotherapy strategy for patients selected to undergo pulmonary metastasectomy from colorectal cancer. Journal of Clinical Oncology, 2004, 22, 3653-3653.	0.8	0
126	BRCA1 status, molecular markers, clinical variables in breast cancer patients with high probability of having an inherited genetic mutation. Journal of Clinical Oncology, 2004, 22, 9648-9648.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Male breast cancer in Parma Province: Descriptive epidemiology, molecular markers and clinical variables. <i>Journal of Clinical Oncology</i> , 2004, 22, 9655-9655.	0.8	0
128	Different expression of BRCA1 status and clinical variables in a sample of Italian women with early onset breast cancer (EOBC). <i>Journal of Clinical Oncology</i> , 2004, 22, 9670-9670.	0.8	0